Sentences with phrase «effects of amphetamine»

There is additional evidence that DA is relevant to the psychotomimetic effects of amphetamine.

The fact that the ability of neuroleptic drugs to antagonize the effects of amphetamine in man and stereotyped behavior in laboratory animals correlates with clinical potency is further evidence that these effects of amphetamine are due to increased DA.

However, this does not specifically link the increased DA turnover to the central effects of amphetamine.

That's a marked difference from smoking, the only other consumption behavior that has been linked to certain genes, says Abraham Palmer, a pharmacogeneticist at the University of Chicago in Illinois who studies how genes regulate the effects of amphetamine.

Our model also explains the performance - enhancing effect of dopamine / noradrenaline reuptake inhibitors on exercise performance in hot conditions, as shown by Watson et al, 33 as well as the reported effects of amphetamines on endurance performance.

Not exact matches

Cocoa also has an uplifting effect on mood due to its content of phenylethylamine, which has a mood elevating effect somewhat akin to amphetamine - type substances.

Most are designed to mimic the effects of cannabis, ecstasy (MDMA) or amphetamines.

In mice with a genetic deletion of DARPP - 32 or with point mutations in phosphorylation sites of DARPP - 32, the effects of D - amphetamine, LSD, and PCP on two behavioral parameters — sensorimotor gating and repetitive movements — were strongly attenuated.

The drugs» effects are similar to those of amphetamines.

We found that when artificial streams were exposed to amphetamine at a concentration similar to what we found in parts of the Gwynns Falls watershed, there were measurable and concerning effects to the base of the aquatic food web.»

The attenuation of MP's effects could also reflect abnormal D2 receptor function, as was previously suggested to explain findings in marijuana - abusing schizophrenic patients, who, despite displaying low DA release, showed increases in psychotic symptoms when challenged with amphetamine (21).

We examined the effect of a dopamine agonist (d - amphetamine) on hippocampal - dependent associative memory in healthy human participants (n = 60).

Susan Amara, USA - «Regulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transporters

Use of amphetamines without a doctor's order, known as nonmedical use, carries a high risk of abuse and dependency, as well as potential harmful side effects such as heart problems and seizures.

Caffeine is a powerful stimulant of the nervous system having an effect similar to the ones related to amphetamines, albeit weaker.

That's why the researchers did a small trial to look at the slimming effect of D - amphetamine in obese people.

The finding that amphetamine stimulates brain DA turnover in man — as demontrated by an increased CSF HVA after probenecid without an increase in CSF 3 - methoxy -4-hydroxy-phenyl glycol (MHPG), the major metabolite of NE — suggests that amphetamine has a more potent effect on brain DA than NE.

This conclusion is also strengthened by the report that the α - adrenergic blocker, phenoxybenzamine, and the β - blocker, propranolol, did not inhibit the euphoriant effects of highâ $ dose amphetamine in detoxified amphetamine addicts.